Skip to main content
Fig. 7 | Molecular Cancer

Fig. 7

From: Two nanoformulations induce reactive oxygen species and immunogenetic cell death for synergistic chemo-immunotherapy eradicating colorectal cancer and hepatocellular carcinoma

Fig. 7

The combination therapy of Nano-FdUMP/Nano-Folox and anti-PD-L1 antibody for CRC liver metastasis mouse model. a) Treatment schedule and IVIS images. b) The liver metastases over a 16-day period (n = 6, * p < 0.05 and ** p < 0.01). c) Animal survival (median survival: PBS = 20 days, anti-PD-L1 antibody = 21 days, and Nano-FdUMP/Nano-Folox = 48 days) (n = 6, *** p < 0.01). d) Immunofluorescent staining of tumors on Day 12 (DNA fragments = green; nuclei = blue) to determine apoptosis (n = 4, ** p < 0.01, relative to Nano-FdUMP/Nano-Folox). e) Level of CD8+ T cells, CD4+ T cells, memory CD8+ T cells, memory CD4+ T cells, and activated DCs in tumors on Day 12, analyzed by flow cytometry (n = 4, * p < 0.05 and NS = no significance). f) The mRNA expression of IFN-γ, IL-12, IL-4, IL-6 and IL-10 in tumors on Day 12 (n = 4, * p < 0.05 and NS = no significance)

Back to article page